Table 5.
Association of PTTG1IP variable number of tandem repeats (VNTR) with metastasis risk stratified by immunochemical index
| Characters | Genotype of PBF VNTR (metastasis/no metastasis) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Status with 5 repeats | Status with 6 repeats | Status with repeat length | Biallelic‐repeats dose | |||||||||
| */* | 5/* + 5/5 | OR (95% CI) | #/# | 6/# + 6/6 | OR (95% CI) | S/S | S/L + L/L | OR (95% CI) | Low | High | OR (95% CI) | |
| ER (+) | 94/84 | 54/77 | 0.66 (0.41–1.06) | 44/55 | 104/106 | 1.19 (0.72–1.96) | 15/19 | 133/142 | 0.97 (0.46–2.04) | 33/32 | 115/129 | 0.81 (0.45–1.46) |
| PR (+) | 76/78 | 47/71 | 0.69 (0.42–1.14) | 36/52 | 87/97 | 1.30 (0.77–2.23) | 15/19 | 108/130 | 0.89 (0.42–1.90) | 29/30 | 94/119 | 0.73 (0.39–1.35) |
| PR (−) | 18/6 | 7/6 | 0.39 (0.08–2.00) | 8/3 | 17/9 | 0.35 (0.05–2.39) | 0/0 | 25/12 | n.d | 4/2 | 21/10 | 1.09 (0.11–10.58) |
| HER2 (+) | 33/27 | 18/16 | 0.95 (0.37–2.47) | 19/10 | 32/33 | 0.69 (0.24–1.96) | 6/4 | 45/39 | 0.82 (0.20–3.36) | 12/11 | 39/32 | 1.48 (0.48–4.57) |
| HER2 (−) | 59/56 | 33/60 | 0.53 (0.30–0.94) | 22/44 | 70/72 | 1.76 (0.95–3.26) | 9/15 | 83/101 | 1.15 (0.47–2.83) | 21/21 | 71/95 | 0.70 (0.35–1.42) |
| ER (−) | 58/36 | 61/31 | 1.23 (0.64–2.37) | 43/21 | 76/46 | 0.82 (0.41–1.65) | 18/12 | 101/55 | 1.29 (0.55–3.06) | 31/16 | 88/51 | 0.89 (0.42–1.87) |
| PR (+) | 19/18 | 18/15 | 1.14 (0.44–2.96) | 17/15 | 20/18 | 0.95 (0.36–2.50) | 8/7 | 29/26 | 0.93 (0.29–2.94) | 12/9 | 25/24 | 0.74 (0.26–2.10) |
| PR (−) | 39/18 | 43/16 | 1.32 (0.52–3.35) | 26/6 | 56/28 | 0.42 (0.13–1.39) | 10/5 | 72/29 | 1.48 (0.39–5.62) | 19/7 | 63/27 | 0.88 (0.29–2.70) |
| HER2 (+) | 29/20 | 37/12 | 1.86 (0.74–4.68) | 29/13 | 37/19 | 0.86 (0.34–2.17) | 14/5 | 52/27 | 0.86 (0.26–2.84) | 21/7 | 45/25 | 0.68 (0.24–1.96) |
| HER2 (−) | 27/15 | 24/19 | 0.76 (0.29–2.01) | 14/8 | 37/26 | 0.95 (0.30–3.02) | 4/7 | 47/27 | 2.93 (0.73–11.84) | 10/9 | 41/25 | 1.35 (0.45–4.02) |
Odds ratios (OR) and 95% confidence intervals (CI) were calculated using unconditional logistic regression with the */*, #/#, S/S and low dose of biallelic‐repeats genotypes as reference groups, respectively, and adjusted for age and age at menarche. Bold values indicate statistical significance. *, other repeat alleles rather than five repeats; #, other repeat alleles rather than six repeats; +, positive; −, negative; ER, estrogen receptor; HER2, epidermal growth factor receptor 2; L, long (≥6); n.d, no data; PR, progesterone receptor; S, short (≤5).